June 3, 2008 – Acceleware’s AxRecon image reconstruction solution for micro-computed tomography (CT) was adopted by Eli Lilly, in hopes of speeding up image reconstruction times used in the pharmaceutical development process.
Acceleware’s AxRecon works as a turn-key solution with a low cost of operation that fits into the current CT scanner workflow, reportedly generating fully reconstructed, quality images completed hours sooner than before.
Acceleware’s application acceleration platform utilizes the power of NVIDIA Graphic Processing Units (GPUs) to increase the speed of sophisticated computations, saving on power and space while maintaining image quality, according to the company.
Pharmaceutical researchers regularly use CT Scanners in the drug development process to observe the effects of novel drug candidates on anatomy. However, deriving value from CT Scanners for drug development is hampered by slow image reconstruction time due to insufficient computing power. This reduces efficiency as well as the researcher’s ability to maximize the capabilities of advanced imaging equipment. Acceleware’s solution is said to eliminate the computer processing bottleneck in image reconstruction workflow and speed up the evaluation of drug effectiveness.
For more information: www.acceleware.com
March 30, 2026 
